Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

Experimental hematology - 1 Dec 2009

Laubach Jacob P, Fu Ping, Jiang Xiaohong, Salter Kelly H, Potti Anil, Arcasoy Murat O

Abstract excerpt

OBJECTIVE: Polycythemia vera (PV) is characterized by erythrocytosis associated with the presence of the activating JAK2(V617F) mutation in a variable proportion of hematopoietic cells. JAK2(V617F) is detected in other myeloproliferative neoplasms, does not appear to be the PV-initiating event, and its specific role in deregulated erythropoiesis in PV is incompletely understood. We investigated the pathogenesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Culture Media, Serum-Free

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythroid Precursor Cells

Share to Erythropoiesis

Share to Erythropoietin

Share to MAP Kinase Kinase Kinase 1

Share to Polycythemia Vera

Share to Stem Cell Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 19815050
DOI: 10.1016/j.exphem.2009.09.009
PMCID: PMC2783925

Genes

EPO
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.PMID 19815050Read ↗

The <i>JAK2</i> V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationSemantic proximity Read ↗

Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F.Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Semantic proximity Read ↗

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraSemantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.Semantic proximity Read ↗

Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.Semantic proximity Read ↗

Advances in polycythemia vera and lessons for acute leukemia.Semantic proximity Read ↗

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.Semantic proximity Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.